Last reviewed · How we verify
Clinically prescribed direct acting antiviral
Direct-acting antivirals inhibit viral enzymes or proteins required for viral replication, preventing the virus from reproducing within host cells.
Direct-acting antivirals inhibit viral enzymes or proteins required for viral replication, preventing the virus from reproducing within host cells. Used for Viral infection (specific virus and indication not specified in provided information).
At a glance
| Generic name | Clinically prescribed direct acting antiviral |
|---|---|
| Also known as | DAA treatment |
| Sponsor | Massachusetts General Hospital |
| Drug class | Direct-acting antiviral (DAA) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Direct-acting antivirals (DAAs) target specific viral proteins such as proteases, polymerases, or other essential enzymes needed for the viral life cycle. By binding to and inhibiting these molecular targets, DAAs block viral replication at a specific step, reducing viral load. This class has been most extensively developed and clinically validated for hepatitis C virus (HCV) and more recently for SARS-CoV-2 and other viral infections.
Approved indications
- Viral infection (specific virus and indication not specified in provided information)
Common side effects
- Headache
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- Prophylaxis With Direct-acting Antivirals for Kidney Transplantation From HCV-Infected Donors to Uninfected Recipients (NA)
- Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Lung Transplant (PHASE4)
- DAA Treatment in Donor HCV-positive to Recipient HCV-negative Heart Transplant (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: